

1 Protection provided by vaccination, booster 2 doses and previous infection against covid- 3 19 infection, hospitalisation or death over 4 time in Czechia

5 Supporting Information, S1 File: Methods

6 A Cox regression with time-varying covariates

7 We use a Cox proportional Hazard model with time varying covariates. In the
8 model, we let each individual to go through the several “vaccination” (covari-
9 ate `VaccStatus`) and “post-infection” (`InfPrior`) states. The outcomes (events)
10 are either (a confirmed) infection (`Infected`, may be repeated), hospitalization
11 (`Hospitalized`), or death of covid (`DeadByCov`). Deaths of other reasons are also
12 recorded (`DeadByOther`), leading to withdrawal from the study at the time of the
13 event. Fixed (non-time-dependent) covariates include sex (`Sex`) and age category
14 (`AgeGr`). The input for the Cox regression model (`coxph` from `survival` R package)
15 consists of one or more records for each subject, each referring to an interval from `T1`
16 to `T2`, containing the values of covariates `InfPrior`, `VaccStatus`, `AgeGr`, `Sex` valid in
17 $[T1, T2)$ and indicators of outcomes `Infected`, `Hospitalized`, `DeadByCov`, `DeadByOther`,
18 happening at `T2`. There may be (and typically is) several records for each subject,
19 each corresponding to a time interval in which the covariates are constant and in
20 the interior of which no events happen.

21 Time is measured in days and we take the day before vaccination started (Dec 26th,
22 2021) as time zero in all analyses except for the reinfection analysis in which we
23 take May 1st, 2020 (two months after the first cases) as time zero. The `VaccStatus`
24 categorical covariate may take the following values:

25 **_Unvacc:** The subject is not vaccinated (this value is taken as reference).

26 ***V_first1*** The subject is from 14 to $14 + 61 - 1 = 74$ days after the first dose of
27 vaccine *V* but not 14 days or more after a second dose. *V* may be A–ChAdOx1-
28 S, M–mRNA-1273 or P–BNT162b2.

29 ***V_first2plus***: The subject is 75 days or more after the first dose of vaccine *V* but
30 not 14 days or more after a second dose.

31 ***VX***: The subject is between $14 + (X - 1) * 61$ and $14 + (X) * 61 - 1$ days after the
32 final dose of vaccine *V* but not 7 days or more after a booster. In addition to
33 P/M/A, the vaccine may be also J (Ad26.COV2-S).

34 **Vboost:** The subject is 7 days or more after a booster by vaccine V .

35 The **InfPrior** may take the following values:

36 **None:** The subject has not been infected previously.

37 **X:** The subject is from $(X - 1) \times p$ to $X \times p - 1$ days after the last positive test for
38 covid, where $p = 61$ in the analyses of reinfections and $p = 91$ in the remaining
39 analyses.

40 **rest:** In reinfection analysis: the subject is $9 \times 61 = 549$ days or more after the last
41 positive test, in the remaining analyses: the subject is $3 \times 91 = 273$ days or
42 more after the last positive test.

43 By default, for each subject, the intervals cover the entire period from 26th. De-
44 cember 2020 to 20. November 2021. The period is shortened if either

- 45 • The subject is reported to die
- 46 • The subject is reported to obtain booster by ChAdOx1-S or Ad26.COV2-S
- 47 • The subject is $4 \times 61 + 14 = 258$ days after the final dose and has not yet
48 obtained a booster.
- 49 • The subject is hospitalized (only in the hospitalization analysis)
- 50 • The subject is infected or gets a vaccine (only in the reinfection analysis)

51 For better understanding, here we show a complete data record of four sample sub-
52 jects (A0,A1,A2,A3) determined to the infection analysis. All of them are recorded
53 from $T=0$ (26.12.2020) until $T=314$ (4.11.2021).

54 A0 is not vaccinated and gets infected at the last day of the study. A1 has not
55 been infected before, but gets infected (Day 140) and dies of covid-19 (Day 150)
56 before being vaccinated. A2 became first-dose vaccinated with BNT162b2 on day
57 114, was infected between the first and second dose (day 142), got the second dose
58 (day 220) and survives until the end of the study. A3 has been infected 20 days
59 before beginning of the study, gets vaccinated by Ad26.COV2-S (Day 150) and is
60 not infected until the end.

61 The input of **coxph** routine is displayed in Table 1. Note that there is typically more
62 records than events as each follow-up covariate has to have its own interval. Table
63 2 gives details on the performed analyses.

Table 1: Sample input to Cox regression.

Sub- ject	T1	T2	Inf- ected	Dead- Covid	Dead- Other	Inf- Prior	Vacc- Status	Age- Gr	Sex
A0	0	313	1	0	0	_none	_unvacc	40-44	F
A0	313	314	0	0	0	1	_unvacc	40-44	F
A1	0	140	1	0	0	_none	_unvacc	75-79	F
A1	140	150	0	1	0	_none	_unvacc	75-79	F
A2	0	128(=114+14)	0	0	0	_none	_unvacc	45-49	M
A2	128	142	1	0	0	_none	P_first1	45-49	M
A2	142	189(=128+61)	0	0	0	1	P_first1	45-49	M
A2	189	220	0	0	0	1	P_first2plus	45-49	M
A2	220	233(=142+91)	0	0	0	1	P1	45-49	M
A2	233	281(=220+61)	0	0	0	2	P1	45-49	M
A2	281	314	0	0	0	2	P2	45-49	M
A3	0	71(=0-20+91)	0	0	0	1	_unvacc	40-44	F
A3	71	162(=71+91)	0	0	0	2	_unvacc	40-44	F
A3	162	164(=150+14)	0	0	0	3	_unvacc	40-44	F
A3	164	225(=164+61)	0	0	0	3	J1	40-44	F
A3	225	253(=162+91)	0	0	0	3	J2	40-44	F
A3	253	286(=225+61)	0	0	0	rest	J2	40-44	F
A3	286	314	0	0	0	rest	J3	40-44	F

Table 2: Details on analyses. $X\Delta Inf$ – a dummy equal to one if the VaccStatus value corresponds to vaccine X and the interval $T1 \geq \text{Jul-01-2021}$, $*$ – 61 days periods (otherwise 91 day periods for InfPrior).

Analysis	Ages	Event	Covariates
Infections	all	Infected	InfPrior, VaccStatus, Sex, AgeGr
Reinfections	all	Infected	InfPrior*, Sex, AgeGr
Hospitalizations	all	Hospitalized	VaccStatus, Sex, AgeGr
Deaths	all	DeadByCov	VaccStatus, Sex, AgeGr
Boosters	all	Infected	InfPrior, VaccStatus, Sex, AgeGr
Delta March	70–79	Infected	InfPrior, VaccStatus, Sex, AgeGr, ADeltaInf, JDeltaInf, MDeltaInf, PDeltaInf
Delta April	55–69	Infected	dtto.
Delta May	30–54	Infected	dtto.